Use of biologic agents in ocular manifestations of rheumatic disease.

about

Infliximab for peripheral ulcerative keratitis treatment.Biologic therapy for refractory scleritis: a new treatment perspective.Successful treatment with tocilizumab for refractory scleritis associated with relapsing polychondritis.

P2860

Q38283034-3926BA9C-A07A-4D56-8853-12D18B41D373 Q38576234-E4501DEA-5555-474F-8858-064A3C6D9F14 Q52920664-B76CC109-B90B-461D-8985-F9DFDE81D08A

P2860

Use of biologic agents in ocular manifestations of rheumatic disease.

Item

http://www.wikidata.org/entity/Q40008319

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

2011年學術文章

@zh

2011年學術文章

@zh-hant

name

Use of biologic agents in ocular manifestations of rheumatic disease.

@en

type

Item

label

Use of biologic agents in ocular manifestations of rheumatic disease.

@en

prefLabel

Use of biologic agents in ocular manifestations of rheumatic disease.

@en

P1476

Use of biologic agents in ocular manifestations of rheumatic disease.

@en

P2093

Courtney L Kraus

http://www.w3.org/2001/XMLSchema#string

Susan M Culican

http://www.w3.org/2001/XMLSchema#string

P2860

Extra-articular disease manifestations in rheumatoid arthritis: incidence trends and risk factors over 46 years

Behçet's disease: a new target for anti-tumour necrosis factor treatment

High-dose daclizumab for the treatment of juvenile idiopathic arthritis-associated active anterior uveitis.

Ophthalmologic manifestations of rheumatic diseases.

Short-term trial of etanercept in Behçet's disease: a double blind, placebo controlled study.

Cytokines in Sjogren's syndrome: potential therapeutic targets.

Rituximab versus cyclophosphamide for ANCA-associated vasculitis.

Recombinant human tumor necrosis factor receptor Fc fusion protein (Etanercept): experience as a therapy for sight-threatening scleritis and sterile corneal ulceration.

Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective study.

Adalimumab in the therapy of uveitis in childhood

P304

203819

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1155/2012/203819

http://www.w3.org/2001/XMLSchema#string

P478

2012

http://www.w3.org/2001/XMLSchema#string

P577

2011-12-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221732870

http://www.w3.org/2001/XMLSchema#string

P698

22229035

http://www.w3.org/2001/XMLSchema#string

P932

3246731

http://www.w3.org/2001/XMLSchema#string

Use of biologic agents in ocular manifestations of rheumatic disease.

about

P2860

P2860

Use of biologic agents in ocular manifestations of rheumatic disease.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P5875

P698

P932